Retrospective Analysis of Posaconazole Suspension Dosing Strategies in a Pediatric Oncology Population: Single-Center Experience

Limited data on optimal posaconazole dosing strategies for pediatric patients exist. In this study, we found that the median initial dose in patients who achieved a posaconazole plasma concentration of 0.7 μg/mL was 22.8 mg/kg per day whereas the median initial dose in those who did not reach the target concentration was 15.8 mg/kg per day; this result suggests that higher initial doses might be warranted.

[1]  J. Hoffman,et al.  Posaconazole Therapeutic Drug Monitoring in Pediatric Patients and Young Adults with Cancer , 2013, The Annals of pharmacotherapy.

[2]  P. Johann,et al.  Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation , 2012, BMC Infectious Diseases.

[3]  A. McLachlan,et al.  Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting Concentration , 2012, Antimicrobial Agents and Chemotherapy.

[4]  D. Marriott,et al.  Posaconazole Exposure-Response Relationship: Evaluating the Utility of Therapeutic Drug Monitoring , 2012, Antimicrobial Agents and Chemotherapy.

[5]  J. Gobburu,et al.  Exposure–Response of Posaconazole Used for Prophylaxis Against Invasive Fungal Infections: Evaluating the Need to Adjust Doses Based on Drug Concentrations in Plasma , 2010, Clinical pharmacology and therapeutics.

[6]  Patricia Muñoz,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  P. Chandrasekar,et al.  Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft‐versus‐Host Disease , 2007, Pharmacotherapy.

[8]  J. Lipton,et al.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.

[9]  V. Preedy,et al.  European Organization for Research and Treatment of Cancer , 2010 .

[10]  J. Perfect,et al.  Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.